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Schizophrenia (SZ) is a biochemically complex disorder characterized bywidespread defects
in multiple metabolic pathways whose dynamic interactions, until recently, have been
difﬁcult to examine. Rather, evidence for these alterations has been collected piecemeal,
limiting the potential to inform our understanding of the interactions amongst relevant
biochemical pathways. We herein review perturbations in purine and neurotransmitter
metabolism observed in early SZ using a metabolomic approach. Purine catabolism is an
underappreciated, but important component of the homeostatic response of mitochondria
to oxidant stress.We have observed a homeostatic imbalance of purine catabolism in ﬁrst-
episode neuroleptic-naïve patients with SZ (FENNS). Precursor and product relationships
within purine pathways are tightly correlated. Although some of these correlations persist
across disease or medication status, others appear to be lost among FENNS suggesting
that steady formation of the antioxidant uric acid (UA) via purine catabolism is altered
early in the course of illness. As is the case for within-pathway correlations, there are
also signiﬁcant cross-pathway correlations between respective purine and tryptophan
(TRP) pathway metabolites. By contrast, purine metabolites show signiﬁcant cross-
pathway correlation only with tyrosine, and not with its metabolites. Furthermore, several
purine metabolites (UA, guanosine, or xanthine) are each signiﬁcantly correlated with
5-hydroxyindoleacetic acid (5-HIAA) in healthy controls, but not in FENNS at baseline
or 4-week after antipsychotic treatment. Taken together, the above ﬁndings suggest
that purine catabolism strongly associates with the TRP pathways leading to serotonin
(5-hydroxytryptamine, 5-HT) and kynurenine metabolites. The lack of a signiﬁcant correla-
tion between purine metabolites and 5-HIAA, suggests alterations in key 5-HT pathways
that may both be modiﬁed by and contribute to oxidative stress via purine catabolism in
FENNS.
Keywords: schizophrenia, first-episode psychosis, neuroleptic-naïve, oxidative stress, purine catabolism,
monoamine neurotransmitters
INTRODUCTION
Schizophrenia (SZ) is a common and highly disabling mental
disorder without a clearly identiﬁed pathophysiology. A num-
ber of putative mechanisms have been proposed to explain the
etiopathogenesis and illness presentation of SZ including abnor-
mal neuronal development, impaired neurotransmission, viral
infections in utero, autoimmune dysfunction, and many others.
Extensive, albeit fragmentary, ﬁndings from neurochemical and
neuroendocrine studies of SZ (Javitt and Laruelle, 2006) have not
provided conclusive evidence for any speciﬁc etiologic theory of
SZ, perhaps due to etiopathogenetic heterogeneity (Tandon et al.,
2009). However, there exists a point of convergence for many of
these theoretical models, one that occurs at the level of the neu-
ronal membrane, which is the site of neurotransmitter receptors,
ion channels, signal transduction, and drug effects. Membrane
deﬁcits, speciﬁcally free radical-mediated, can signiﬁcantly alter a
broad range of membrane functions. There is abundant evidence
that alterations in key neurotransmitters can both be modiﬁed
by and contribute to oxidative stress and membrane dysfunction
(Figure 1), suggesting a link among oxidative stress, membrane
dysfunction, and multi-neurotransmitter pathologies in SZ (Yao
and Keshavan, 2011).
METABOLOMIC INVESTIGATION
Schizophrenia is a heterogeneous disease with various abnormal
metabolites involving multiple biochemical pathways. Therefore,
to identify candidate pathological process(es) that account for
the constellation of clinical and biological features in SZ, it is
necessary to simultaneously evaluate multiple metabolites in a
network of interacting biochemical pathways. The development of
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FIGURE 1 | A schematic diagram linking antioxidant defense system, membrane phospholipids, and neurotransmission to pathophysiology in
schizophrenia. Reprinted by permission fromYao and Keshavan (2011).
high-resolution multidimensional separation techniques such as
high-pressure liquid chromatography coupled with a 16-channel
coulometric multi-electrode array system (HPLC–CMEAS), can
lead to revolutionary changes in our understanding at the molec-
ular level (Matson et al., 1984; Kristal et al., 1998; Yao and Cheng,
2004; Rozen et al., 2005; Kaddurah-Daouk et al., 2008). The
resolving power of these methods is superior to one-dimensional
approaches, enabling the comprehensive metabolic analyses par-
ticularly in the targeted biochemical pathways. The HPLC–
CMEAS allows quantitative assays of hundreds to thousands of
low molecular-weight metabolites, in turn permitting identiﬁca-
tion of biomarkers and metabolic maps associated with disease
processes. The data collected from HPLC–CMEAS system reﬂect
ﬁngerprinting of the disorder or state/trait-related markers, which
will greatly improve the predictive diagnostics for phenotypes
that directly involve in the oxidative stress. More signiﬁcantly,
these comprehensive analyses that generate metabolic proﬁles
represent not only biomarkers for disease but also metabolic
maps that can be used to identify speciﬁc genes responsible
for disease. Such metabolic maps provide a different perspec-
tive to biomedical research in further understanding the effects
of therapeutic, nutritional, toxicological, and environmental
interventions.
ANTIOXIDANT DEFENSE SYSTEM
GLUTATHIONE REDOX COUPLING AND NITRIC OXIDE
SIGNALING
Free radicals are unstable atoms or molecules with odd (unpaired)
electron(s) that can start a toxic chain reaction on important cel-
lular components such as DNA, or the cell membrane. Biological
systems have evolved complex protective strategies against free
radical toxicity. Under physiological conditions the potential for
free radical-mediated damage is kept in check by the antioxidant
defense system (AODS), comprising a series of enzymatic and
non-enzymatic components. These enzymes act cooperatively at
different sites in the free radical pathways. A dynamic state is kept
in check during the redox coupling under normal conditions (Yao
et al., 2006). By contrast, lack of such correlations in brains of
patients with SZ point to a disturbance of redox coupling mech-
anisms in the AODS, possibly resulting from a decreased level of
glutathione (GSH) aswell as age-related decreases of oxidizedGSH
and GSH reductase activities. Taken together, our previous data
showing altered membrane dynamics and AODS enzyme activi-
ties, and ﬁndings from other investigators (Ranjekar et al., 2003;
Othmen et al., 2008; Virit et al., 2009; Matsuzawa and Hashimoto,
2011) are consistent with the notion of free radical-mediated
neurotoxicity in SZ (Yao et al., 2001).
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There are multiple pathways to the production of excess free
radical generation and subsequent oxidative stress. One such path-
way is the formation of peroxynitrite by a reaction of nitric oxide
(NO) and superoxide radical. In human brain, NO is metabo-
lized primarily in the form of nitrate. A signiﬁcantly increased
level of NO was found in brains with SZ than those of normal and
non-schizophrenic psychiatric controls (Yao et al., 2004a). Because
the reaction of NO with free thiols competes with the same sub-
strate (e.g., GSH), the excessive NO formation may further lead to
signiﬁcant depletion of GSH in SZ.
PURINE CATABOLISM
In addition to GSH redox coupling mechanism and NO signaling,
purine catabolism (Figure 2) may be a previously unappreciated
component of the homeostatic response of mitochondria to oxi-
dant stress and may play a critical role in slowing progressive
mitochondrial dysfunction in certain disease states (Kristal et al.,
1999). Mitochondria process most of the cellular oxygen to pro-
vide energy that drives almost all metabolic processes, and also
are the site of signiﬁcant free radical production. About 3% of all
oxygen consumed is converted to superoxide, and subsequently
to hydrogen peroxide (Floyd, 1996). Thus there is an enormous
and continuous free-radical burden. Antioxidant systems keep
this in check. When the equilibrium between pro-oxidant and
antioxidant systems are disturbed in favor of the former, mito-
chondrial damage can occur. Mitochondrial membranes, similar
to neuronal membranes, are vulnerable to lipid peroxidation.
Any impairment in mitochondrial oxidative phosphorylation can
lead to a broad range of cellular disturbances, including altered
neurotransmission, increased DNA damage (Bogdanov et al.,
2000; Schulz et al., 2000) and decreased DNA repair, and ﬁnally
cell death. Cytochrome c oxidase is a key enzyme in the mitochon-
drial electron transport chain. Decreased activity of this enzyme
has been reported in the frontal cortex and caudate nucleus of
schizophrenic patients. Several lines of evidence suggest decreased
oxidative metabolism in some brain areas in SZ (Yao et al., 2004a;
Yao et al., 2006), and may be explained in part by mitochondrial
dysfunction.
An early study by Kristal et al. (1999) indicated that purine
catabolism may contribute to mitochondrial antioxidant defense
by producing uric acid (UA). Failure to maintain elevated xan-
thine (Xan) andUAoccurred contemporaneouslywith progressive
mitochondrial dysfunction. Thus, purine catabolism appears to be
a homeostatic response of mitochondria to oxidant stress and may
protect against progressive mitochondrial dysfunction in certain
disease states (Kristal et al., 1999).
During the de novo synthesis of purine nucleotides, many reac-
tions require a great deal of energy utilizing the hydrolysis of
adenosine triphosphate (ATP). To provide “energy saving” for the
cell, the purinebases canbe reutilized via“salvagepathways”(Cory,
1982) by converting adenine, guanine (G), or hypoxanthine (Hx)
to adenosine monophosphate (AMP), guanosine monophosphate
(GMP), or inosine monophosphate (IMP), respectively (shown
dotted arrow in Figure 2). The unsalvaged Hx is then converted to
Xan, which is further converted to UA by Xan oxidase. In man, UA
is the ﬁnal product of purine catabolism (Linden andRosin, 2006),
which has been implicated as a risk factor and cause of numerous
pathological conditions (see below).
FIGURE 2 | Altered purine catabolism in first-episode neuroleptic-
naïve patients with schizophrenia. Red arrows indicate shifts toward
an increase of xanthosine and a decrease of uric acid productions in
FENNS patients at baseline. Reactions shown with dotted lines
represent the “salvage pathways,” which purine bases can be reutilized
resulting in considerably energy saving for the cell. ADP, adenosine
diphosphate; AMP, adenosine monophosphate; ATP, adenosine
triphosphate; DA, deaminase; GMP, guanosine monophosphate;
GTP, guanosine triphosphate; HGPRT, hypoxanthine-guanine
phosphoribosyltransferase; HL, hydrolase; IMP, inosine monophosphate;
NP, nucleoside phosphorylase; PRPP, 5-phosphoribosyl pyrophosphate;
SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; XMP,
xanthosine monophosphate; XO, xanthine oxidase. Reprinted by
permission fromYao et al. (2010b).
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DUAL ROLES OF URIC ACID IN AODS
Contrary to the traditional understanding as a metabolically inert
and waste compound without any physiological signiﬁcance, UA
is a natural antioxidant contributing to approximately 60% of
the free radical scavenging activity in human blood (Ames et al.,
1981). Past studies have demonstrated that UA and inosine (pre-
cursor of UA) may be beneﬁcial in the treatment of oxidative
stress-related neurodegenerative diseases (Hooper et al., 2000;
Spitsin et al., 2001; Scott et al., 2002; Liu et al., 2006; Du et al.,
2007).
Uric acid is a selective antioxidant (Figure 3) that removes
superoxide by preventing the degradation of superoxide dismu-
tase and subsequently inhibits its reaction with NO to form
peroxynitrite (van der Veen et al., 1997). Moreover, UA can
neutralize peroxynitrite (Keller et al., 1998) and hydroxyl rad-
icals (Davies et al., 1986) to inhibit protein nitration (Pacher
et al., 2007) and lipid peroxidation (Muraoka and Miura, 2003),
respectively. Recent investigations further indicated that UA may
operate as a protective factor mediated through astroglia for
dopaminergic neurons from glutamate toxicity (de Lau et al.,
2005; Du et al., 2007). Moreover, UA prevents the propaga-
tion of oxidative stress from the extracellular to the intracellular
milieu by preserving the integrity of the plasma membrane at the
lipid–aqueous interface boundary (Guerreiro et al., 2009). High
K+-induced depolarization ampliﬁes neuroprotection provided
by UA through a mechanism involving Ca2 elevation and extra-
cellular signal-regulated kinases½ (ERK1/2) activation (Figure 3).
Thus, decreased plasma UA levels may reﬂect decreased ability of
the body to prevent superoxide and peroxynitrite from acting on
cellular components and damaging the cell (Kutzing and Firestein,
2007). Previously, we have demonstrated signiﬁcant decreases of
plasma UA levels in either ﬁrst-episode neuroleptic-naïve patients
with SZ (FENNS) patients (Reddy et al., 2003) or clinically stable
patients with chronic SZ (Yao et al., 1998). Similarly, low levels of
UA have been linked to a variety of neurodegenerative diseases
including Alzheimer’s disease, multiple sclerosis, optic neuritis,
and Parkinson’s disease (Church and Ward, 1994; Toncev et al.,
2002; Knapp et al., 2004; de Lau et al., 2005; Kim et al., 2006;
Bogdanov et al., 2008; Ascherio et al., 2009).
On the other hand, at increased levels, UA is considered as
a marker of oxidative stress (Becker, 1993; Strazzullo and Puig,
2007) due to accumulation of reactive oxygen species (Hayden
and Tyagi, 2004). Abnormally high levels of UA have been related
to cardiovascular disease, gout, hypertension, and renal disease
(Jossa et al., 1994; Freedman et al., 1995; Kang et al., 2002; Choi
et al., 2005; Bos et al., 2006). Although some studies have indicated
that UA may play a role in the development or progression of such
diseases (Saito et al., 1978; Jossa et al., 1994; Waring et al., 2000;
Kang et al., 2002; Bos et al., 2006), it remains unclear whether an
increased UA contributes to the cause or simply a consequence of
these pathologic conditions (Kutzing and Firestein, 2007).
In addition, an altered purine catabolism has also been demon-
strated in subjects with cocaine addition (Patkar et al., 2009)
or with opioid dependence (Mannelli et al., 2009), although
plasma UA levels remained unchanged. It is not clear whether
such changes in purine metabolites without affecting plasma UA
levels would eventually lead to oxidative damage in substance
FIGURE 3 | Dual role of uric acid in the antioxidant defense system.
Uric acid can neutralize peroxynitrite and hydroxyl radicals to inhibit protein
nitration and lipid peroxidation, respectively. At increased levels, however,
uric acid may be considered as a marker of oxidative stress due to
accumulation of reactive oxygen species. CAT, catalase; GSH, glutathione;
ERK1/2, extracellular signal-regulated kinases½, LOO
•, lipid peroxyl radical;
LVCa, L-type voltage-gated calcium channel; NO, nitric oxide; NO•2, nitrogen
dioxide radical; NO−2 , nitrite; O
−
2 , superoxide anion; ONOO
−, peroxynitrite;
OH•, hydroxyl radical; SOD, superoxide dismutase; Xan, xanthine; XO,
xanthine oxidase. Reprinted by permission fromYao et al. (2010b).
abusers. Nevertheless, taken together, UA may serve as either
antioxidant or pro-oxidant in the AODS as illustrated in
Figure 3.
HOMEOSTATIC IMBALANCE OF PURINE CATABOLISM
Using a targeted electrochemistry based metabolomics (HPLC–
CMEAS) platform, we compared metabolic signatures consisting
of six plasma purine metabolites simultaneously between FENNS
(n = 25) and healthy controls (HC, n = 30). We also com-
pared these metabolites between FENNS at baseline (FENNS-BL)
and 4 weeks (FENNS-4w) after antipsychotic treatment (Yao
et al., 2010b). Signiﬁcantly higher levels of xanthosine (Xant)
and lower levels of G were seen in both patient groups com-
pared to HC subjects. Moreover, the ratios of G/guanosine (Gr),
UA/Gr, and UA/Xant were signiﬁcantly lower, whereas the ratio
of Xant/G was signiﬁcantly higher in FENNS-BL patients than
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in HC subjects (Table 1). Such changes remained in these same
patients after 4 weeks of treatment (FENNS-4w) with the excep-
tion that the ratio of UA/Gr was completely normalized. During
purine catabolism, both conversions from Gr to G and from Xant
to Xan are reversible. Decreased ratios of product to precursor
suggested a shift favorable to the Xant production resulting in
decreased UA levels in the FENNS (Figure 2). More importantly,
such an imbalance in purine catabolism is observed independent
of treatment since patients were neuroleptic-naïve at entry into the
study.
In addition, within the purines’ pathway, all three groups had
signiﬁcant correlations between G and UA, and Xan and Hx. By
contrast, correlations of UA with each of Xan and Hx, and corre-
lation of Xan with Gr were all quite signiﬁcant for the HC group
but not for the FENNS group before or after treatment. Thus,
there are tightly correlated precursor and product relationships
within purine pathways; although some of these correlations per-
sist across disease or medication status, others appear to be lost
among FENNS patients. Taken together, the potential for steady
formation of antioxidant UA from purine catabolism is altered
early in the course of illness (Yao et al., 2010b).
CROSS-PATHWAY CORRELATIONS BETWEEN PURINE
METABOLITES AND MONOAMINE NEUROTRANSMITTERS
The purinergic neurotransmission hypothesis was originally pro-
posed in 1972 (Burnstock, 1972). Although ATP is widely rec-
ognized as an intracellular energy source for carrying out many
biochemical reactions, it is also considered as a co-transmitter with
glutamate, noradrenaline, acetylcholine, dopamine, and gamma-
aminobutyric acid (GABA) in both central and peripheral nervous
systems (Burnstock, 2007, 2009). Following the stimulation (e.g.,
electrical excitation) of brain, the adenine nucleosides that are
stored in vesicles in nerve varicosities are released (Pull and McIl-
wain, 1972; Sulakhe and Phillis, 1975) by exocytosis to act on
postjunctional receptors for ATP on smooth muscle. ATP is bro-
ken down by ATPases and 5′-nucleotidase to adenosine, which is
taken up by varicosities to be resynthesized and reincorporated
into vesicles. Adenosine is further broken down extracellularly
by adenosine deaminase to inosine and Hx (Figure 2) and then
removed by circulation (Burnstock, 1972).
In the study of normal behavior, purinergic signaling has been
linked to learning and memory, sleep and arousal, locomotor
activity and exploration, feeding behavior, and mood and moti-
vation (Burnstock et al., 2011). On the other hand, a disordered
purinergic signaling has been implicated in a variety of neurode-
generative diseases (Alzheimer’s, Parkinson’s, and Huntington’s
disease, multiple sclerosis, and amyotrophic lateral sclerosis) as
well as neuropsychiatric diseases (SZ and mood disorders). Pre-
viously, a conspicuous relationship was observed between purine
and monoamine metabolite concentrations in cerebrospinal ﬂuid
(CSF) during depressive illness suggesting the presence of a parallel
purinergic and monoaminergic activation in the brain (Niklasson
et al., 1983).
To test whether plasma purine and monoamine metabolite
concentrations were correlated in SZ, we studied previously pub-
lished measurements (Yao et al., 2010a,b) of six purine metabolites
(Hx, Xan, Xant, G, Gr, UA) for which concomitant mea-
surements of 14 monoamine metabolites, tryptophan (TRP),
serotonin (5-hydroxytryptamine, 5-HT), 5-hydroxyindoleacetic
acid (5-HIAA), tryptamine (TRPA), melatonin (MEL), kynure-
nine (KYN), 3-hydroxykynurenine (3-OHKY), tryptophol
(TPOL), tyrosine (TYR), L-3,4-dihydroxyphenylalanine (L-
DOPA), Normetanephrine (NMET), homovanillic acid (HVA),
3-methoxy-4-hydroxyphenylglycol (MHPG), and vanillylman-
delic acid (VMA), were also available from HC (n = 30) and
FENNS-BL (n = 25) and FENNS-4w (n = 25). Using Q–Q plots
and a univariate correlation test (Johnson and Wichern, 1998), we
found these data not to be approximately normal nor consistently
transformable to approximate normality for all three datasets (HC,
BL, 4w). Kendall’s tau values and the p-values for rejection of H0:
tau = 0, were thus computed for all pairs consisting of one purine
metabolite and one monoamine metabolite within each of the
three datasets. Correction of alpha for multiple tests (252) was
done by the Bonferroni procedure.
The Kendall’s tau analysis found positive correlations that were
signiﬁcantly different from 0 in the HC group, for cross-pathway
Table 1 | Comparisons of ratios of product to precursor in purine pathway.
Ratios HC FENNS-BL FENNS-4w p
HC vs BL* HC vs 4w* BL vs 4w†
G/Gr 0.89 ± 0.61§ 0.37 ± 0.30 0.48 ± 0.72 0.0004¶ 0.0009 0.8949
Xan/G 46.33 ± 85.46 81.92 ± 98.86 66.68 ± 50.91 0.0211 0.0015 0.7112
UA/Gr 7371 ± 4325 4152 ± 2193 7047 ± 5556 0.0015 0.4967 0.0025
UA/G 11998 ± 11525 16529 ± 14751 23771 ± 14948 0.0614 <0.0001 0.0236
UA/Xant 5073 ± 4845 1298 ± 972 2184 ± 4310 0.0021 0.0067 0.5782
Xant/G 10.48 ± 15.58 42.02 ± 75.08 31.35 ± 27.93 0.0009 0.0001 0.2752
*Wilcoxon rank sum test.
†Wilcoxon signed rank sum test.
§Data obtained fromYao et al. (2010b).
¶Signiﬁcance with p < 0.0033 after the Bonferroni correction.
G, guanine; Gr, guanosine; Xan, xanthine; UA, uric acid; Xant, xanthosine.
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purine and monoamine metabolite pairs (Table 2) as follows: (1)
for UA with TRP, 5-HIAA, MEL, KYN, and TYR; (2) for G with
TRP, TYR, and possibly (trend) with MEL and KYN; (3) for GR
with TYR; and (4) for Xan with TYR, and possibly (trend) with
5-HIAA. Many of these same correlations were also signiﬁcant or
possibly signiﬁcant for the BL and 4w groups, with the following
notable exceptions. The correlations between each of UA and Xan
with 5-HIAA were much weaker and far from signiﬁcance for BL
and 4w patients, suggesting possible group differences among HC,
BL,and 4w. Formal testing for equality of correlations among these
groups, the next step, will require larger group numbers than are
available with the present dataset.
To summarize, in HC, the purine and TRP pathways show
extensive cross-correlations (all positive) among their respective
member metabolites, whereas the TYR pathway shows signiﬁcant
cross-correlation with purines only via tyrosine. These relation-
ships are generally seen for the BL and 4w groups as well. It may be
that there are general dietary (precursor amino acids and purines
are both high in many foods), hydration, hepatic, or other inﬂu-
ences that affect purines and indoleamines and TYR similarly.
However, the correlation of 5-HIAA with UA and Xan appear
to be much weaker in the BL and 4w groups. We have already
observed that BL patients have weaker correlations within the
TRP pathway, e.g., 5-HIAA with TRP (tau = 0.09 BL, tau = 0.69
HC), which may occur when dietary associations are overcome by
other rate-limiting pathway controls based on physiological needs
for serotonin neurotransmitter (Yao et al., 2010a). The 4w group
appears to have very little association between 5-HIAA and Xan,
perhaps due to treatment with atypical neuroleptic drugs, which
block serotonin 5-HT2, as well as dopamine D2, receptors, bring-
ing more variables to inﬂuence the 5-HIAA metabolic product of
5-HT. The positive correlations in human CSF of Xan and several
monoamines including 5-HIAA have been noted earlier (Niklas-
son et al., 1983) and between UA and 5-HIAA (Degrell and Nagy,
Table 2 | Across pathway correlations between 6 purine and 14 monoamine metabolites by the Kendall’s tau method.
Metabolites Kendall’s tau rank correlations
HC (n = 30) FENNS-BL (n = 25) FENNS-4w (n = 25)
I II tau p tau p tau p
Significant correlations among all three groups
UA TRP 0.6598 <0.0001 0.7122 <0.0001 0.6400 <0.0001
UA MEL 0.5034 0.0001 0.5800 <0.0001 0.5400 0.00017
UA KYN 0.6184 <0.0001 0.6800 <0.0001 0.6333 <0.0001
UA TYR 0.7287 <0.0001 0.7200 <0.0001 0.6467 <0.0001
G TRP 0.5034 0.0001 0.5843 <0.0001 0.5667 <0.0001
G TYR 0.5816 <0.0001 0.5333 0.0002 0.5733 <0.0001
G MEL 0.4667 0.0003 0.5267 0.0002 0.5600 <0.0001
Significant correlations present only in HC and FENNS-BL but not FENNS-4w
Gr TYR 0.5681 <0.0001 0.6118 <0.0001 0.3022 0.0516
G KYN 0.4805 0.0002 0.5200 0.0003 0.4933 0.0006
Significant correlations present only in HC but not FENNS groups
UA 5-HIAA 0.5310 <0.0001 0.1733 0.2336 0.3667 0.0109
Xan 5-HIAA 0.4759 0.0002 0.1733 0.2336 0.0133 0.9441
Xan TYR 0.5264 <0.0001 0.4000 0.0054 0.4133 0.0041
Significant correlations present only in FENNS-BL but not in HC and FENNS-4w
UA TRPA 0.3563 0.0060 0.6333 <0.0001 0.4267 0.0030
Gr TRP 0.4613 0.0006 0.6440 <0.0001 0.3255 0.0359
Gr MEL 0.4127 0.0021 0.6118 <0.0001 0.2480 0.1112
Gr KYN 0.4127 0.0021 0.6256 <0.0001 0.3952 0.0107
Gr 3-OHKY 0.3885 0.0038 0.6403 <0.0001 0.3649 0.0187
Significant correlations present only in FENNS groups but not in HC
UA 3-OHKY 0.3977 0.0022 0.7114 <0.0001 0.5710 <0.0001
Data were obtained fromYao et al. (2010a,b).
Signiﬁcance with p < 0.000197 after the Bonferroni correction.
HC, healthy control subjects; FENNS, ﬁrst-episode neuroleptic-naïve patients with schizophrenia; BL, baseline; 4w, 4-week after antipsychotic treatment; UA, uric acid;
G, guanine; Gr, guanosine; Xan, xanthine; TRP, tryptophan; MEL, melatonin; KYN, kynurenine; TYR, tyrosine; 5-HIAA, 5-hydroxyindoleacetic acid; TRPA, tryptamine;
3-OHKY, 3-hydroxykynurenine.
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1990). It is notable that correlations are maintained between UA
or G and metabolites in other branches of the TRP pathway (MEL,
KYN) which are not involved in serotonin neurotransmission, for
HC and patient groups.
PURINERGIC SIGNALING, CLINICAL IMPROVEMENT, AND
NEUROLOGICAL DEFICITS
Associations between purine metabolites and clinical and neuro-
logical symptomswere examinedbefore and after 4w antipsychotic
treatment (Yao et al., 2012). A lower initial proportion of product
(UA) to precursor (guanine) measured at baseline was associated
with greater improvement in clinical functioning 1 month later
(Figure 4). Improvement in clinical functioning was associated
with initial levels of UA and G in the FENNS patients. The ini-
tial severity of clinical dysfunction may thus be important to this
relationship. As a group, the average level of clinical function-
ing reﬂected impairment at both time points, with mean values
(<40) falling within the range typically observed for former inpa-
tients likely to be readmitted to hospital (Endicott et al., 1976).
Descriptively, degree of clinical improvement achieved by the
patient group in the above study (Yao et al., 2012) represented an
increase from“Unable to function in almost all areas. . .” at baseline
to “Major impairment in several areas. . .” 1 month later (Global
Assessment Scale or GAS anchor points). It may be appropriate,
therefore, to qualify interpretation of ﬁndings based on this degree
of severity.
Neurological abnormalities are a core feature of SZ even at
the time of their ﬁrst episode of psychosis without antipsy-
chotic drug treatment (Rubin et al., 1994; Gupta et al., 1995;
Keshavan et al., 2003; Mohr et al., 2003; Sanders et al., 2004).
Moreover, neurological signs are correlated with clinical symp-
toms in unmedicated patients (Sanders et al., 2000). Signiﬁcant
heritability, or familial inﬂuence, has also been reported for sev-
eral aspects of neurologic-related responding (Sanders et al., 2006),
which suggest that neurological deﬁcits may represent a biological
marker of SZ risk. Recently, we have shown that purine metabo-
lites were also linked to neurological and cognitive symptoms in
the FENNS patients (Yao et al., 2012). Firstly, motor neurolog-
ical signs (Buchanan and Heinrichs, 1989) recorded at baseline
were associated with initial or baseline level of the ratio of Xant
to Gr, indicating the higher a patient’s initial or baseline ratio of
Xan to Gr, the greater his or her motor neurological signs was
before initiating treatment with antipsychotic medications. Sec-
ondly, sensory-integrative neurological signs were predicted by
baseline level of UA, which suggests that lower levels of UA were
associated with greater impairment in sensory processing tasks.
The above ﬁndings thus suggest an association between optimal
levels of purine byproducts and dynamics in clinical symptoms
and adjustment, as well as in the integrity of sensory and motor
processing.
PURINERGIC SIGNALING AND PLATELET ACTIVATION
Purinergic signaling is an important link among platelet acti-
vation, vascular thrombosis, and inﬂammation (Eltzschig et al.,
2012). Mammalian cells contain high levels of ATP. Under patho-
logic conditions such as inﬂammation, there is an increased release
of ATP. Extracellular adenosine is formed predominately from a
series of enzymatic conversion from ATP, adenosine diphosphate
(ADP), and AMP to adenosine (Figure 2). Adenosine signaling
is terminated by uptaking adenosine from extracellular space to
intracellular space and is then rapidly metabolized to inosine
through adenosine deaminase (Eltzschig et al., 2006) or converted
back to AMP through adenosine kinase (Morote-Garcia et al.,
2008). Inhibition of adenosine kinase by cyclosporine resulting in
increased levels of extracellular adenosine may contribute, at least
in part, to the anti-inﬂammatory effects of cyclosporine (Spychala
and Mitchell, 2002).
In human platelets, serotonin (5-HT) ampliﬁes the aggregation
induced by ADP (McBride et al., 1989; de Clerck, 1990), which is
mediated by the 5-HT2 receptor complex. Thus, the magnitude
FIGURE 4 | Associations between clinical improvement at 4 weeks and ratio of uric acid to guanine in first-episode neuroleptic-naïve patients with
schizophrenia at baseline (A) or at 4-week (B) after antipsychotic treatment. GAS, Global Assessment Scale; ln, natural logarithm. Reprinted by permission
fromYao et al. (2012).
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of serotonin ampliﬁcation of ADP-induced platelet aggregation
and dense granule secretion (DGS) may provide us with an index
to evaluate the platelet serotonin responsivity. In both normal
control subjects and clinically stable patients with chronic SZ
(with antipsychotic treatment), our laboratory demonstrated a
robust increase of platelet aggregation in response to synergistic
effects of ADP and 5-HT (Yao et al., 1996). Moreover, increases in
5-HT ampliﬁcation were inversely correlated with the psychosis
severity. The magnitude of 5-HT ampliﬁcation, however, was
not signiﬁcantly different in those same patients after haloperidol
withdrawal. Recently, we have further shown that FENNS patients
have signiﬁcantly lower 5-HT ampliﬁcation than the normal con-
trol subjects (Reddy et al., 2007). The blunted platelet serotonergic
responsivity may thus be associated with SZ per se, independent
of drug effects. The magnitude of 5-HT ampliﬁcation on ADP-
induced platelet aggregation, however, can be augmented in SZ
patients after eicosapentaenoic acid (EPA) supplementation (Yao
et al., 2004b).
DO PERIPHERAL INDICES OF METABOLIC DEFICITS ALSO
REFLECT SIMILAR CHANGES IN THE BRAIN?
Whether peripheral indices of abnormal metabolites reﬂect sim-
ilar changes in the brain and/or are related to presumed brain
events are frequently raised by the reviewers in the grant applica-
tions and manuscript submissions. This issue has been vigorously
debated because of examples in the literature, where peripheral
measures either failed to adequately reﬂect central pathophysi-
ology or did not serve as reliable biological markers. Therefore,
in principle, the majority of research investigators believe that
peripheral ﬁndings do not reﬂect the similar changes in the
brain. However, in an editorial in Molecular Psychiatry, Wong
and Licinio (2005) have eloquently stated that this belief has per-
vaded the ﬁeld and has undermined our ability to conﬁdently
use the powerful tools of contemporary biology in order to dis-
sect the biology of psychiatric disorders through investigation
of peripheral markers, particularly those measured in peripheral
blood.
Substantial evidence has been accumulated that reveals
metabolic defects in both the peripheral and central tissue of
patientswith SZ (see reviews by Skosnik andYao,2003;Yao and van
Kammen, 2004; Mahadik andYao, 2006; Yao and Keshavan, 2011).
Moreover, direct correlations between the peripheral (red blood
cell, RBC) and central (31-phosphorus magnetic resonance spec-
troscopy, 31P MRS) phospholipids and polyunsaturated fatty acids
(PUFAs) were shown in SZ patients (Richardson et al., 2001; Yao
et al., 2002). Additionally, platelets and ﬁbroblasts have been used
as models for nerve cells in a variety of neuropsychiatric diseases
(Farmer, 1980; Mahadik and Mukherjee, 1996). These ﬁndings
support the notion that metabolic defects are present in both neu-
ral and extra-neural tissues, but the functional consequences may
differ. For example, changes in peripheral metabolites may play a
role in clinical presentation and outcome during the early course
of SZ (Condray et al., 2011; Yao et al., 2012).
Moreover, there are several paradigmatic conditions such
as Down syndrome, phenylketonuria, and various lipidoses
(Scriver et al., 1989) where the metabolic abnormalities are
expressed in both neural and peripheral tissues, but the functional
consequences are most profound in the central nervous system
(CNS). A recent review by Andrews and Neises (2012) also sug-
gest that research examining the mechanism of how traumatic
events are linked to peripheral blood mononuclear cell functions
and biomarkers may offer improved diagnoses and treatments for
post-traumatic stress disorder patients. This paradigm may also
apply to SZ. A recent study by comparison of peripheral and cen-
tral SZ biomarker proﬁles, Harris et al. (2012) have concluded that
the systemic nature of SZ provides added validity of investigating
blood-basedbiomarkers in SZ. If peripheral indices parallel central
metabolic defects, and perhaps also neuromorphometric and/or
neuroimaging ﬁndings, then there exists the possibility that alter-
ations in peripheral indices on longitudinal follow-up (repeated
measures) can usefully reﬂect central membrane function over the
course of illness.
CONCLUSION AND PERSPECTIVES
During the purine catabolism, there are three major purine
bases and their corresponding ribonucleosides, which consist of
adenine/adenosine, G/Gr, and Hx/inosine (Figure 2). As men-
tioned above, we have observed that a homeostatic imbalance of
purine catabolism is present in FENNS. There are tightly corre-
lated precursor and product relationships within purine pathways.
Although some of these correlations persist across disease or
medication status, others appear to be lost among FENNS (Yao
et al., 2010b). Similar ﬁndings of lacking a control mechanism
used by HC subjects were also demonstrated in the TRP pathway
from these same FENNS patients (Yao et al., 2010a). When taken
together, these observations suggest that a steady formation of the
important antioxidant UA via purine catabolism is altered early in
the course of illness.
Moreover, we have applied Kendall’s tau to assess correlations
between purine metabolites and monoamine neurotransmitters
with the Bonferroni corrections. Correlations between TYR, TRP,
and some purines may originate in the diet or other common
organism-wide inﬂuences, but some of these appear to be lost
as these compounds undergo further transformations along their
respective pathways. For bothHC and patients, purinemetabolites
normally show signiﬁcant cross-pathway correlation only with
TYR, not with its metabolites, where correlations may be lost
due to internal inﬂuences over neurotransmitter production. Fur-
thermore, several purine metabolites (UA, Gr, or Xan) are each
signiﬁcantly correlated with TRP in all subjects. But purine corre-
lations with 5-HIAA seem to be present only in HC subjects, not in
FENNS at baseline or 4weeks after antipsychotic treatment. Again,
the loss of correlations in the pathway metabolite may be lost in
patients due to illness-related, and also perhaps treatment inﬂu-
ences, on 5-HIAA, since the TRP–5-HIAA correlation is appears
weakened in patients (Yao et al., 2010a).
In conclusion, SZ is a heterogeneous disease with various
abnormal metabolites involving multiple biochemical pathways.
There is abundant evidence that alterations in key neurotransmit-
ters can both be modiﬁed by and contribute to oxidative stress
and membrane dysfunction (Figure 1), suggesting a link between
these pathophysiological processes in SZ.GSHredox coupling,NO
signaling, and purine catabolism are the key pathways involving
the AODS. We have previously demonstrated a homeostatic
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imbalance of purine catabolism (Yao et al., 2010b) and blunted
platelet serotonergic responsivity (Yao et al., 1996;Yao et al., 2004b;
Reddy et al., 2007) in FENNS. In this “Hypothesis and Theory”
paper, we propose that the altered purine metabolites have sig-
niﬁcantly impacts on not only within the purine catabolism but
also across the TRP pathways involving the serotonin and KYN
metabolism.
Firstly, several purine metabolites (UA, Gr, or Xan) are each
signiﬁcantly correlated with TRP in all subjects. However, purine
correlations with 5-HIAA seem to be present only in HC subjects,
not in FENNS at baseline or 4 weeks after antipsychotic treat-
ment (Table 2). Conversion of serotonin to N-acetylserotonin
by serotonin N-acetyltransferase may be upregulated in the same
set of FENNS patients, possibly related to the observed alteration
in TRP–5-HIAA correlation (Yao et al., 2010a). Lacking signiﬁ-
cant correlations between purine metabolites (UA and Xan) and
5-HIAA suggest that alterations in key serotonin pathways may
both be modiﬁed by and contribute to oxidative stress via purine
catabolism in FENNS.
Secondly, we have shown that a neurotoxic product of TRP
metabolism, 3-OHKY, predicts severity of clinical symptoms dur-
ing the early phase of illness and before exposure to antipsychotic
drugs (Condray et al., 2011). Baseline level of 3-OHKY may also
predict the degree of clinical improvement following brief treat-
ment with antipsychotics. In the present paper, we have further
demonstrated that levels of 3-OHKY were signiﬁcantly correlated
with levels of either Gr or UA in this same sample set. Consider-
ing the unique functional roles of UA (the end product of purine
catabolism) as both antioxidant and pro-oxidant, the homeostatic
balance of UA appears to play a vital role of regulatory functions
in not only the AODS but also the KYN pathway. The KYN path-
way that produces neurotoxic and neuroinhibitory compounds is
regulated by the dopamine metabolites,VMA and HVA,which has
been implicated in the pathogenic mechanisms underlying SZ.
Lastly, optimum levels of purine metabolites have been
associated with the dynamics of clinical symptoms and ther-
apeutic improvements, which may lead to discovery of novel
targets for drug development. Interestingly, allopurinol, which
is a structural isomer of Hx and is an inhibitor of the Xan oxi-
dase, can improve SZ symptoms either when given alone or as
add-on medication to haloperidol (Lara et al., 2001). Xan oxi-
dase is responsible for the successive oxidation of Hx and Xan
(http://en.wikipedia.org/wiki/Xanthine), leading to the formation
of UA (Pacher et al., 2006). Therefore, allopurinol may regulate
levels of not only UA but also the extracellular adenosine (via
feedback inhibition). Future investigations are required to estab-
lish therapeutic target for purinergic drugs in treatment of SZ
patients.
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